Nath Bio-Genes (India) Ltd
NSE: NATHBIOGEN BSE: 537291
₹171.21
(-1.81%)
Wed, 20 May 2026, 04:37 am
Market Cap3.25B
PE Ratio8.11
Dividend1.17
Process Industries
Agricultural Commodities/Milling
24.5KNath Bio-Genes (India) Analysis
dividend
- Unable to evaluate Nath Bio-Genes (India)'s dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Nath Bio-Genes (India)'s dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Nath Bio-Genes (India) is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Nath Bio-Genes (India) is profitable, therefore cash runway is not a concern.
- Nath Bio-Genes (India) is profitable, therefore cash runway is not a concern.
- Debt is covered by short term assets, assets are 6.8x debt.
- Nath Bio-Genes (India)'s cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (20.7% vs 12.5% today).
- Interest payments on debt are well covered by earnings (EBIT is 8.4x coverage).
- Nath Bio-Genes (India)'s level of debt (12.5%) compared to net worth is satisfactory (less than 40%).
- Debt is not well covered by operating cash flow (13.6%, less than 20% of total debt).
- High level of physical assets or inventory.
management
- The tenure for the Nath Bio-Genes (India) board of directors is about average.
- Satish's remuneration is about average for companies of similar size in India.
- Satish's compensation has been consistent with company performance over the past year, both up more than 20%.
misc
- Nath Bio-Genes (India) is not covered by any analysts.
- Nath Bio-Genes (India) has significant price volatility in the past 3 months.
past
- Nath Bio-Genes (India) has delivered over 20% year on year earnings growth in the past 5 years.
- Nath Bio-Genes (India) used its assets more efficiently than the IN Food industry average last year based on Return on Assets.
- Nath Bio-Genes (India) has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
- Nath Bio-Genes (India)'s earnings growth has exceeded the IN Food industry average in the past year (31% vs 20.5%).
- Nath Bio-Genes (India)'s 1-year earnings growth is less than its 5-year average (31% vs 32.4%)
- Nath Bio-Genes (India) has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
value
- 537291 matched the India Market (-14.5%) over the past year.
- BSE:537291 is up 17.6% outperforming the Food industry which returned 5% over the past month.
- BSE:537291 is up 17.6% outperforming the market in India which returned 8% over the past month.
- Nath Bio-Genes (India) is overvalued based on assets compared to the IN Food industry average.
- Nath Bio-Genes (India) is overvalued based on earnings compared to the IN Food industry average.
- Nath Bio-Genes (India) is overvalued based on earnings compared to the India market.
- 537291 underperformed the Food industry which returned 18.8% over the past year.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800